tickrz reports
tickrz rank
D
Boston Scientific Corp (BSX)
Healthcare | Health Services
29.43  0.03%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankD / 426Warren Buffett RankD / 460
Pure Value RankD / 439Dividend RankD / NO DIVIDEND
Moat RankD / 417Financial Strength RankC / 277
Growth RankD / 400Momentum RankB / 158
BSX vs HEALTH SERVICES SECTOR & S&P 500
VALUATION
BSXSECTORS&P 500
P/E RATIO51.9731.619.61
EV/EBITDA RATIO30.4316.911.89
P/S RATIO4.73.62.06
P/B RATIO5.665.53.15
QUALITY
RETURN ON EQUITY11.71%15.64%13.85%
RETURN ON CAPITAL9.5%50.61%10.02%
NET MARGIN4.14%8.18%9.77%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY81%
INTEREST COVERAGE5.28x
CURRENT RATIO0.75
GROWTH
5 YR EPS GROWTH-2.92%
5 YR SPS GROWTH1.93%
5 YR BPS GROWTH-8.8%
About tickrz
Key Concepts
Great Investors
tickrz Report
tickrz rank D / 426
Boston Scientific Corp receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking D / 439Warren Buffett ranking D / 460
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Boston Scientific Corp's valuation score is comprised of a P/E ratio of 52x, a P/B ratio of 5.7x, a P/S ratio of 4.7x, and an EV/EBITDA ratio of 30.4x. Boston Scientific Corp ranks 439 out of the S&P 500 constituents on valuation--a relatively weak score.Boston Scientific Corp ranks 460 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Boston Scientific Corp is probably not for you.

quality
moat D / 417financial strength C / 277
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.Boston Scientific Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 5.28x, a debt/equity ratio of 81% and a Moat Rank of 417 translate to a weak Financial Strength score.


momentum B / 158
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 25.62% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 158. Based on its 12 month stock performance, Boston Scientific Corp will not appeal to momentum investors.

yield D / NO DIVIDEND
value + yield
Boston Scientific Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth D / 400
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its -2.9% 5 year annualized EPS growth, 1.9% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -8.8% speak to its relatively poor ranking.

Boston Scientific Corp (BSX)
Healthcare | Health Services
29.43  0.03%


tickrz rank
D
VALUATION RATIOS
P/E Ratio51.97x
P/B Ratio5.66x
P/S Ratio4.7x
EV/EBITDA Ratio30.43x
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY81%
INTEREST COVERAGE5.28x
CURRENT RATIO0.75
MOAT
ROE11.71%
ROIC9.5%
Net Margin4.14%
GROWTH
5 YR EPS GROWTH-2.92%
5 YR SPS GROWTH1.93%
5 YR BPS GROWTH-8.8%

TICKRZ RANK
Boston Scientific Corp receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Boston Scientific Corp's valuation score is comprised of a P/E ratio of 52x, a P/B ratio of 5.7x, a P/S ratio of 4.7x, and an EV/EBITDA ratio of 30.4x. Boston Scientific Corp ranks 439 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Boston Scientific Corp ranks 460 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Boston Scientific Corp is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.

FINANCIAL STRENGTH
Boston Scientific Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 5.28x, a debt/equity ratio of 81% and a Moat Rank of 417 translate to a weak Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 25.62% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 158. Based on its 12 month stock performance, Boston Scientific Corp will not appeal to momentum investors.

VALUE + YIELD
Boston Scientific Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its -2.9% 5 year annualized EPS growth, 1.9% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -8.8% speak to its relatively poor ranking.